Showing 1 - 20 results of 38 for search '"трансплантация аутологичных гемопоэтических стволовых клеток"', query time: 0.68s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
    Academic Journal

    Contributors: 0

    Source: Almanac of Clinical Medicine; Vol 52, No 2 (2024); 55-65 ; Альманах клинической медицины; Vol 52, No 2 (2024); 55-65 ; 2587-9294 ; 2072-0505

    File Description: application/pdf

  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    Academic Journal

    Source: Malignant tumours; Том 12, № 4 (2022); 14-21 ; Злокачественные опухоли; Том 12, № 4 (2022); 14-21 ; 2587-6813 ; 2224-5057

    File Description: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/1007/712; Gillesen S., Sauve N., Collette L. et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT) : Results From the IGCCCG Update Consortium. J Clin Oncol. 2021; 39 (14) : 1563–1574. DOI:10.1200/JCO.20.03296.; Mead G., Cullen M., Huddart R. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. British Journal of cancer. 2005; 93 : 178–184. DOI:10.1038/sj.bjc.6602682.; Kondagunta G., Bacik J., Donadio A., et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005; 23 (27) : 6549–6555. DOI:10.1200/JCO.2005.19.638.; Nichols C., Tricot G., Williams S., et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I / II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989; 7 (7) : 932–939. DOI:10.1200/JCO.1989.7.7.932.; Beyer J., Kramar A., Mandanas R., et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996; 14 (10) : 2638–2645. DOI:10.1200/JCO.1996.14.10.2638.; Einhorn L., Williams S., Chamness A., et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007; 357 (4) : 340–348. DOI:10.1056/NEJMoa067749.; Feldman D., Sheinfeld J., Bajorin D., et al. TI–CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010; 28 (10) : 1706–1713. DOI:10.1200/JCO.2009.25.1561.; Lorch A, Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol. 2011; 29 (16) : 2178–2184. DOI:10.1200/JCO.2010.32.6678.; Pico J., Rosti G., Kramar A., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005; 16 (7) : 1152–1159. DOI:10.1093/annonc/mdi228.; Tryakin A., Fedyanin M., Matveev V. et al. Practical guidelines for the treatment of germ cell tumors in men. Malignant Tumors: RUSSCO Practice Guidelines. 2021; 11 (3s2) : 556–585 (in Russ.) DOI:10.18027/2224-5057-2021-11-3s2-34.; National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Testicular cancer. Available at: https://www.nccn.org/professionals/physician_gls (Accessed on July 03, 2022).; Fizazi K., Culine S., Kramar A. et al. Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors. J Clin Oncol. 2004; 22 : 3868–3876. DOI:10.1200/JCO.2004.04.008.; McHugh D., Feldman D. Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. Adv Urol. 2018 : 7272541. DOI:10.1155/2018/7272541.; https://www.malignanttumors.org/jour/article/view/1007

  17. 17
  18. 18
  19. 19
  20. 20